PROVIDENCE, R.I., Oct. 12, 2011/PRNewswire/ -- Isis Biopolymer announced the appointment of Chris Hobson as its new president and chief executive officer, effective October 1, 2011. Concurrently, Mr. Hobson has been appointed to the Isis Biopolymer board of directors. Isis Biopolymer, based in Providence, RI, has pioneered advancements in polymer chemistry, miniaturization and electronics packaging to provide “active” transdermal infusion technology for the next generation delivery of active ingredients. This infusion technology is appropriate for both Rx and consumer applications, and is the foundation for the company’s recent launch of the Biobliss anti-aging line of skin care products.
Mr. Hobson brings to Isis Biopolymer eighteen years of successful leadership in early-stage ventures, with experience-building high-performance teams, raising capital and developing successful business models. As CEO, Mr. Hobson will lead Isis Biopolymer to optimize the Biobliss rollout, identify new technology and market opportunities and establish the company’s value proposition for long-term growth.
David Poor, Chairman of Isis Biopolymer Board of Directors, has been the interim CEO during the recruitment process. “After an exhaustive search, we are proud to announce Chris as CEO,” said Mr. Poor. “We have great confidence in Chris’ abilities and energy, and we’re very excited for the next stage in the company’s growth under his leadership.”
Most recently Mr. Hobson served as COO of the mobile research and advertising start-up TxtEagle, where he helped position the business and raise $8.5m in Series-A financing. In 2009, he co-founded and co-led the $7.4m financing of Bandgap Engineering, which develops high-efficiency solar cells based on nano-structured silicon. Prior to Bandgap, he was SVP of Operations at eCredit, where he helped engineer a turnaround that led to a successful exit in 2006. Mr. Hobson began his career in consumer brand management at Procter & Gamble where he ran a $30 million portfolio of brands in the Beauty Care division. He completed his B.A. at McGill University, and his M.B.A. at Harvard Business School.
“I am extremely excited to join the Isis Biopolymer team,” said Hobson. “Isis combines all of the key criteria that I was looking for in my next venture: break-through technology and intellectual property that is poised to disrupt a huge market; an excellent team; and sophisticated, value-added investors.”
ABOUT ISIS BIOPOLYMER, INC.
Isis Biopolymer, Inc. is a leader in the development and sales of innovative transdermal products. Isis’s patented and patent pending intelligent transdermal patch leverages key advancements in microprocessor technology, electronic packaging and conductive materials. The Biobliss Patch is the first of many transdermal products Isis is developing. Isis Biopolymer is located in Providence, Rhode Island, in the heart of the Knowledge District. For more information, visit: www.isisbiopolymer.com.
Biobliss is available today at www.biobliss.com.
The Biobliss conversation continues on Facebook.com/biobliss and on Twitter @BIOBLISS.
Note: All brand and product names references belong to their registered owners.
SOURCE Isis Biopolymer
